Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization

Reuters

2025/11/05

Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization

Datavault AI Inc. has announced the signing of a $10 million worldwide exclusive license agreement with Scilex Holding Company for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568504-en) on November 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581771754"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581771754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581771754?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 01:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581771754","market":"nz","top_or_hot":-1,"title":"Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DVLT\">Datavault AI Inc.</a> has announced the signing of a $10 million worldwide exclusive license agreement with <a href=\"https://laohu8.com/S/SCLX\">Scilex Holding Company</a> for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568504-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDatavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 01:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DVLT\">Datavault AI Inc.</a> has announced the signing of a $10 million worldwide exclusive license agreement with <a href=\"https://laohu8.com/S/SCLX\">Scilex Holding Company</a> for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568504-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL4ggFnV:1","article_id":"2581771754","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581771754","pubTimestamp":1762276678,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Datavault AI Inc. has announced the signing of a $10 million worldwide exclusive license agreement with Scilex Holding Company for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SCLX":"Scilex Holding Company","BK4141":"半导体产品","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","DVLT":"Datavault AI Inc."},"translate_title":"Datavault AI向Scilex授予价值1000万美元的生物技术资产代币化独家许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVLT":0.9,"NDAQ":0.9,"SCLX":0.9},"content_text":"Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization\n    \n\nDatavault AI Inc. has announced the signing of a $10 million worldwide exclusive license agreement with Scilex Holding Company for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568504-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}